Invention Publication
- Patent Title: MESOTHELIN-TARGETED CD40 AGONISTIC MULTISPECIFIC ANTIBODY CONSTRUCTS FOR THE TREATMENT OF SOLID TUMORS
-
Application No.: US18417708Application Date: 2024-01-19
-
Publication No.: US20240150481A1Publication Date: 2024-05-09
- Inventor: Xin YU , Jackson EGEN , Fernando GARCES , Shunsuke TAKENAKA , AeRyon KIM , Deepali SAWANT
- Applicant: Amgen Inc.
- Applicant Address: US CA Thousand Oaks
- Assignee: Amgen Inc.
- Current Assignee: Amgen Inc.
- Current Assignee Address: US CA Thousand Oaks
- The original application number of the division: US17127629 2020.12.18
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61P35/04 ; C07K16/30
Abstract:
The present invention relates to a human agonistic CD40 multispecific antibody construct for treatment of solid tumors by engineering a molecule that specifically targets the CD40 pathway on tumor-associated APCs, without systemic CD40 activation.
Information query
